Abstract |
Although γδ-T cell-based tumor immunotherapy using phosphoantigens to boost γδ-T cell immunity has shown success in some cancer patients, the clinical application is limited due to the rapid exhaustion of Vγ9Vδ2-T cells caused by repetitive stimulation from phosphoantigens and the profoundly immunosuppressive tumor microenvironment (TME). In this study, using a cell culture medium containing human and viral interleukin-10 (hIL-10 and vIL-10) secreted from EBV-transformed lymphoblastoid B cell lines (EBV-LCL) to mimic the immunosuppressive TEM, we found that the antitumor activity of Vγ9Vδ2-T cells was highly suppressed by endogenous hIL-10 and vIL-10 within the TME. CD137 costimulation could provide an anti-exhaustion signal to mitigate the suppressive effects of IL-10 in TME by suppressing IL-10R1 expression on Vγ9Vδ2-T cells. CD137 costimulation also improved the compromised antitumor activity of Vγ9Vδ2-T cells in TME with high levels of IL-10 in Rag2-/- γc-/- mice. In humanized mice, CD137 costimulation boosted the therapeutic effects of aminobisphosphonate pamidronate against EBV-induced lymphoma. Our study offers a novel approach to overcoming the obstacle of the hIL-10 and vIL-10-mediated immunosuppressive microenvironment by costimulating CD137 and enhancing the efficacy of γδ-T cell-based tumor therapy.
|
Authors | Yujun Pei, Zheng Xiang, Kun Wen, Chloe Ran Tu, Xiwei Wang, Yanmei Zhang, Xiaofeng Mu, Yinping Liu, Wenwei Tu |
Journal | Frontiers in immunology
(Front Immunol)
Vol. 13
Pg. 872122
( 2022)
ISSN: 1664-3224 [Electronic] Switzerland |
PMID | 35784354
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 Pei, Xiang, Wen, Tu, Wang, Zhang, Mu, Liu and Tu. |
Chemical References |
- Immunosuppressive Agents
- Interleukin-10
|
Topics |
- Animals
- Immunosuppressive Agents
- Immunotherapy
- Interleukin-10
(metabolism)
- Lymphocyte Count
- Mice
- Tumor Microenvironment
|